Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the US Food and Drug Administration (FDA) has approved Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Joenja®, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the US for APDS, a rare and progressive primary immunodeficiency. The FDA evaluated

The U.S. Food and Drug Administration (FDA) on Friday approved Dutch firm Pharming Group’s drug to treat a rare genetic disorder that leads to a weakened immune system, the company said. Leniolisib, to be sold under the brand name Joenja, becomes the first approved drug to treat activated phosphoinositide 3-kinase delta syndrome (APDS), a primary immunodeficiency that affects about 1 to 2 people in a million. Joenja is expected to launch in the U.S. in early April and will be available for shipment in mid-April, Pharming said.

Pharming Group ( AMS:PHARM ) Full Year 2022 Results Key Financial Results Revenue: US$205.6m (up 3.4% from FY 2021…

Pharming Group (PHAR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Pharming Group N.V. (“Pharming” or “the Company”) ( Euronext Amsterdam: PHARM / Nasdaq: PHAR) is aware that Silicon Valley Bank Limited (“SVB UK”) has today been sold to HSBC UK Bank plc. This transaction has been facilitated by the Bank of England, in consultation with the Treasury, using powers granted by the Banking Act 2009.

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) is aware that the US Department of the Treasury, the Board of Governors of the Federal Reserve System and the Federal Deposit Insurance Corporation (“FDIC”) issued a joint statement on March 12, 2023 stating that actions have been approved enabling the FDIC to complete its resolution of Silicon Valley Bank (“SVB US”) in a manner that fully protects all depositors. The statement further noted that deposit

Dutch biotech firm Pharming said on Sunday it held $45 million in collapsed U.S. lender Silicon Valley Bank’s British and U.S. units and that it will seek to recover the funds. Pharming said it held $26 million in SVB US and $19 million in SVB UK. “Pharming’s deposits with SVB US are largely uninsured and its deposits with SVB UK largely exceed the applicable protected limit.”

Pharming Group N.V. (“Pharming” or “the Company”)( Euronext Amsterdam: PHARM) (Nasdaq: PHAR) is aware that the Federal Deposit Insurance Corporation (“FDIC”) has been appointed receiver of Silicon Valley Bank (“SVB US”) and that the Bank of England, barring any intervening events, intends to put Silicon Valley Bank UK Limited (“SVB UK”) into insolvency.

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) confirms it will announce its unaudited Full Year 2022 financial results for the year ended December 31, 2022, on Thursday, March 16, 2023.

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces that the first patient has been enrolled in its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children with activated phosphoinositide 3-kinase delta syndrome (APDS). There is currently no approved treatment for this complex and progressive disease caused by genetic variants.

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has decided to shift its assessment of the Marketing Authorisation Application (MAA) for leniolisib to a standard review timetable. Leniolisib is an oral selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor under regulatory review as a treatment for activated phosphoinositide 3-kinase delta syndrome

If you are looking for stocks that are well positioned to maintain their recent uptrend, Pharming Group N.V. Sponsored ADR (PHAR) could be a great choice. It is one of the several stocks that passed through our “Recent Price Strength” screen.

Today we’ll do a simple run through of a valuation method used to estimate the attractiveness of Pharming Group N.V…

With its stock down 8.5% over the past three months, it is easy to disregard Pharming Group (AMS:PHARM). But if you pay…

Pharming Group N.V. (NASDAQ: PHAR) announced data from an interim analysis of its open-label extension study of leniolisib for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, characterized by recurrent infections. The data were shared at the 2022 Annual Meeting of the American Society of Hematology (ASH). The results demonstrate the long-term tolerability of leniolisib, with a median duration on study therapy of just over two years (102 weeks) and five

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces data, including new evidence, from an interim analysis of its open-label extension study evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, to treat adult and adolescent patients with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. Principal investigator V. Koneti Rao, M.D., a staff ph

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces today that the positive results of a Phase 3 clinical trial of the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in adult and adolescent patients with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, have been published in Blood,1 the peer-reviewed international medical journal of the American So

Here is how Pharming Group N.V. Sponsored ADR (PHAR) and POINT Biopharma Global Inc. (PNT) have performed compared to their sector so far this year.

Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost…

If you are looking for stocks that are well positioned to maintain their recent uptrend, Pharming Group N.V. Sponsored ADR (PHAR) could be a great choice. It is one of the several stocks that passed through our “Recent Price Strength” screen.